sa/LId10

sa/LId10 lbtsw From: Woodson C. Merrell M Uebfax Page: 6/11 ILabCorp Patient Report Panto 14172111.**FILIY !x14:01/20/1953 Patient ID: Control ID: f S831, 43092 5paimenrO: 25740043714 Data collated: 09/14/201/ 1255 Local TESTS RESULT FLAG UNITS REFERENCE INTERVAL 'L AB Dna -Sulfate Estradiol Roche ECLIA methodology Uric Acid Uric Acid Please Nbter Phosphorus LDS GOT Amylase Ferritin, Serum Insulin Calcium, Ionised, Serum 181.8 ug/dL 30.9 - 295.6 01 28.3 pg/mL 7.6 - 42.6 01 6.8 mg/dL 3.7 - 8.6 01 01 Therapeutic target for gout patients: <6.0 3.6 213 mg/dL IU/L 2.5 - 4.5 121 - 224 25 IU/L 0 - 65 37 U/L 31 - 124 Kill Follow 47.2 Nigh uIU/mL 2.6 - 24.9 5.3 mg/dL 4.5 - 5.6 01 01 01 01 01 01 Fibrinogen Activity 330 mg/dL 193 - 507 01 Specimen was ultracentrifuged before testing to remove extreme 'Spezia. Results should be interpreted with caution. Magnesium, ESC 5.4 mg/dL 4.2 - 6.8 02 Plasma NOT separated from cells; may falsely decrease ABC Magnesium levels. 0t RN Soap Radian Dr Aracei B Reyes, IC 89 For Avenuo. Reckon, NJ 08889.1800 02 BN WC*" BurtOl9930 Ur: Wiam F Hancock. MD 1447 York NC 27215-3381 For irgairles. sa 01100100 rnaY end en Date 'Mad: 09/18/113 1053 ET PRELIMINARY REPORT This document contairsprrate al/ cordeential Nab Sontaton pound t7 state and Wang taw. II you Ise reotred this /mean In am. pies am 800431.3250 Page 5 af o 1995-zns Spate, Corpaddon of Hadar Holdlegs Al aphis kswwd - Erns* Repollierilort 1/0 EFTA00314043